Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma

Vineeth Sukrithan; Jason Sandler; Rasim Gucalp; Richard Gralla; Balázs Halmos

doi:10.1016/j.cllc.2018.12.013

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma

Vineeth Sukrithan
, Jason Sandler
, Rasim Gucalp
, Richard Gralla
, Balázs Halmos

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	e242-e246
Journal	Clinical lung cancer
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.cllc.2018.12.013
State	Published - May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Checkpoint inhibitor
Immunotherapy
PD-L1
Pembrolizumab
Tumor mutational burden

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2018.12.013

Cite this

@article{915e3ce28b7a43febe7ee0e14f513e21,

title = "Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma",

keywords = "Checkpoint inhibitor, Immunotherapy, PD-L1, Pembrolizumab, Tumor mutational burden",

author = "Vineeth Sukrithan and Jason Sandler and Rasim Gucalp and Richard Gralla and Bal{\'a}zs Halmos",

note = "Funding Information: B.H. is receiving clinical research support from Merck. The remaining authors have stated that they have no conflicts of interest.",

year = "2019",

month = may,

doi = "10.1016/j.cllc.2018.12.013",

language = "English (US)",

volume = "20",

pages = "e242--e246",

journal = "Clinical lung cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma

AU - Sukrithan, Vineeth

AU - Sandler, Jason

AU - Gucalp, Rasim

AU - Gralla, Richard

AU - Halmos, Balázs

N1 - Funding Information: B.H. is receiving clinical research support from Merck. The remaining authors have stated that they have no conflicts of interest.

PY - 2019/5

Y1 - 2019/5

KW - Checkpoint inhibitor

KW - Immunotherapy

KW - PD-L1

KW - Pembrolizumab

KW - Tumor mutational burden

UR - https://www.scopus.com/pages/publications/85060114496

UR - https://www.scopus.com/pages/publications/85060114496#tab=citedBy

U2 - 10.1016/j.cllc.2018.12.013

DO - 10.1016/j.cllc.2018.12.013

M3 - Article

C2 - 30665873

AN - SCOPUS:85060114496

SN - 1525-7304

VL - 20

SP - e242-e246

JO - Clinical lung cancer

JF - Clinical lung cancer

IS - 3

ER -

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this